Rain Therapeutics raises $125m for IPO

Rain Therapeutics, a developer of precision oncology therapeutics, has raised about $125 million for its IPO after pricing its over 7.3 million shares at $17 per share.

ByIris Dorbian

23 April 2021•3 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Briefs

Rain Therapeutics raises $125m for IPO

Cormorant Asset Management

Goldman Sachs

Janus Henderson Investors

Perceptive Advisors

Samsara BioCapital

Related articles